Sanofi is working to "fine-tune" an application to make erectile dysfunction drug Cialis available OTC in the US, marking another potential boost for its consumer health care segment on top of adding Boehringer Ingelheim GMBH's consumer business.
Sanofi 'Fine-Tuning' Cialis OTC Switch Application
Potential Cialis switch and the pending addition of Boehringer Ingelheim's consumer business are the revenue drivers highlighted by company execs on earnings call; second-quarter consumer health product revenues slipped 4.3% to $886.4m as a mild allergy season in the US and economic chaos in Venezuela drag down sales.